Literature DB >> 17682060

Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway.

Imad Shams1, Edyta Rohmann, Veraragavan P Eswarakumar, Erin D Lew, Satoru Yuzawa, Bernd Wollnik, Joseph Schlessinger, Irit Lax.   

Abstract

Lacrimo-auriculo-dento-digital (LADD) syndrome is characterized by abnormalities in lacrimal and salivary glands, in teeth, and in the distal limbs. Genetic studies have implicated heterozygous mutations in fibroblast growth factor 10 (FGF10) and in FGF receptor 2 (FGFR2) in LADD syndrome. However, it is not clear whether LADD syndrome mutations (LADD mutations) are gain- or loss-of-function mutations. In order to reveal the molecular mechanism underlying LADD syndrome, we have compared the biological properties of FGF10 LADD and FGFR2 LADD mutants to the activities of their normal counterparts. These experiments show that the biological activities of three different FGF10 LADD mutants are severely impaired by different mechanisms. Moreover, haploinsufficiency caused by defective FGF10 mutants leads to LADD syndrome. We also demonstrate that the tyrosine kinase activities of FGFR2 LADD mutants expressed in transfected cells are strongly compromised. Since tyrosine kinase activity is stimulated by ligand-induced receptor dimerization, FGFR2 LADD mutants may also exert a dominant inhibitory effect on signaling via wild-type FGFR2 expressed in the same cell. These experiments underscore the importance of signal strength in mediating biological responses and that relatively small changes in receptor signaling may influence the outcome of developmental processes in cells or organs that do not possess redundant signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682060      PMCID: PMC2099236          DOI: 10.1128/MCB.00544-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.

Authors:  H Kouhara; Y R Hadari; T Spivak-Kroizman; J Schilling; D Bar-Sagi; I Lax; J Schlessinger
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

Review 2.  FGFR activation in skeletal disorders: too much of a good thing.

Authors:  M K Webster; D J Donoghue
Journal:  Trends Genet       Date:  1997-05       Impact factor: 11.639

Review 3.  Craniosynostosis: genes and mechanisms.

Authors:  A O Wilkie
Journal:  Hum Mol Genet       Date:  1997       Impact factor: 6.150

4.  Structure and expression of human fibroblast growth factor-10.

Authors:  H Emoto; S Tagashira; M G Mattei; M Yamasaki; G Hashimoto; T Katsumata; T Negoro; M Nakatsuka; D Birnbaum; F Coulier; N Itoh
Journal:  J Biol Chem       Date:  1997-09-12       Impact factor: 5.157

5.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy.

Authors:  G Yan; Y Fukabori; G McBride; S Nikolaropolous; W L McKeehan
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

6.  Keratinocyte growth factor functions in epithelial induction during seminal vesicle development.

Authors:  E T Alarid; J S Rubin; P Young; M Chedid; D Ron; S A Aaronson; G R Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

7.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.

Authors:  M C Naski; Q Wang; J Xu; D M Ornitz
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

8.  Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2).

Authors:  A Orr-Urtreger; M T Bedford; T Burakova; E Arman; Y Zimmer; A Yayon; D Givol; P Lonai
Journal:  Dev Biol       Date:  1993-08       Impact factor: 3.582

9.  Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome.

Authors:  U Schell; A Hehr; G J Feldman; N H Robin; E H Zackai; C de Die-Smulders; D H Viskochil; J M Stewart; G Wolff; H Ohashi
Journal:  Hum Mol Genet       Date:  1995-03       Impact factor: 6.150

10.  Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation.

Authors:  T Spivak-Kroizman; M A Lemmon; I Dikic; J E Ladbury; D Pinchasi; J Huang; M Jaye; G Crumley; J Schlessinger; I Lax
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

View more
  34 in total

Review 1.  Lacrimo-auriculo-dento-digital syndrome: A novel mutation in a Korean family and review of literature.

Authors:  Young Hye Ryu; Jong Kyun Chae; Jung-Wook Kim; Soyoung Lee
Journal:  Mol Genet Genomic Med       Date:  2020-07-26       Impact factor: 2.183

Review 2.  Lacrimal gland development: From signaling interactions to regenerative medicine.

Authors:  Ankur Garg; Xin Zhang
Journal:  Dev Dyn       Date:  2017-08-18       Impact factor: 3.780

Review 3.  Lacrimo-auriculo-dento-digital syndrome with unilateral inner ear dysplasia and craniocervical osseous abnormalities: case report and review of literature.

Authors:  J E Moses
Journal:  Clin Neuroradiol       Date:  2012-08-24       Impact factor: 3.649

4.  Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis.

Authors:  Helen P Makarenkova; Matthew P Hoffman; Andrew Beenken; Anna V Eliseenkova; Robyn Meech; Cindy Tsau; Vaishali N Patel; Richard A Lang; Moosa Mohammadi
Journal:  Sci Signal       Date:  2009-09-15       Impact factor: 8.192

Review 5.  Cell signaling regulation in salivary gland development.

Authors:  Akiko Suzuki; Kenichi Ogata; Junichi Iwata
Journal:  Cell Mol Life Sci       Date:  2021-01-15       Impact factor: 9.261

6.  Clinical and radiographic delineation of Bent Bone Dysplasia-FGFR2 type or Bent Bone Dysplasia with Distinctive Clavicles and Angel-shaped Phalanges.

Authors:  Deborah Krakow; Daniel H Cohn; William R Wilcox; Grace J Noh; Leslie J Raffel; Anna Sarukhanov; Margarita H Ivanova; Moise Danielpour; Dorothy K Grange; Alison M Elliott; Jonathan A Bernstein; David L Rimoin; Amy E Merrill; Ralph S Lachman
Journal:  Am J Med Genet A       Date:  2016-05-30       Impact factor: 2.802

7.  Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Authors:  Michael G Gartside; Huaibin Chen; Omar A Ibrahimi; Sara A Byron; Amy V Curtis; Candice L Wellens; Ana Bengston; Laura M Yudt; Anna V Eliseenkova; Jinghong Ma; John A Curtin; Pilar Hyder; Ursula L Harper; Erica Riedesel; Graham J Mann; Jeffrey M Trent; Boris C Bastian; Paul S Meltzer; Moosa Mohammadi; Pamela M Pollock
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 8.  Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin.

Authors:  Laura M McDonell; Kristin D Kernohan; Kym M Boycott; Sarah L Sawyer
Journal:  Hum Mol Genet       Date:  2015-07-07       Impact factor: 6.150

Review 9.  Molecular pathology of the fibroblast growth factor family.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

10.  An intronic alteration of the fibroblast growth factor 10 gene causing ALSG-(aplasia of lacrimal and salivary glands) syndrome.

Authors:  Kathrin Scheckenbach; Vera Balz; Martin Wagenmann; Thomas K Hoffmann
Journal:  BMC Med Genet       Date:  2008-12-22       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.